Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
Breaking Medicine Technology: